COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
暂无分享,去创建一个
H. Goldschmidt | H. Einsele | P. Sonneveld | M. Boccadoro | M. Mohty | R. Hájek | P. Moreau | H. Avet-Loiseau | F. Gay | X. Leleu | G. Cook | E. Kastritis | E. Terpos | G. Jackson | H. Ludwig | N. Abildgaard | M. Delforge | T. Facon | J. San-Miguel | M. Engelhardt | M. Mateos | M. Cavo | L. Garderet | A. Broijl | S. Zweegman | N. V. D. van de Donk | K. Weisel | F. Schjesvold | J. Caers | C. Driessen | M. Schreder | I. Nijhof | C. Pawlyn | M. Dimopoulos | N. Zojer | M. Beksaç
[1] Junmo Kim,et al. Fatal Systemic Capillary Leak Syndrome after SARS-CoV-2Vaccination in Patient with Multiple Myeloma , 2021, Emerging infectious diseases.
[2] G. Arabia,et al. Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine , 2021, Neurological Sciences.
[3] John D. Davis,et al. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 , 2021, The New England journal of medicine.
[4] M. Dimopoulos,et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment , 2021, Blood Cancer Journal.
[5] R. Myers,et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.
[6] L. Pagano,et al. COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies , 2021, British journal of haematology.
[7] F. Rey,et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.
[8] Thomas P. Fabrizio,et al. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants , 2021, The New England journal of medicine.
[9] A. Yılmaz,et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey , 2021, The Lancet.
[10] P. Kalra,et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine , 2021, The New England journal of medicine.
[11] S. Jagannath,et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma , 2021, Cancer Cell.
[12] M. Sadarangani,et al. Intentions of public school teachers in British Columbia, Canada to receive a COVID-19 vaccine , 2021, Vaccine: X.
[13] J. Hepojoki,et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants , 2021, Nature Communications.
[14] H. Ludwig,et al. Compliance With Vaccination Recommendations Among Patients With Multiple Myeloma: A Real World Experience , 2021, HemaSphere.
[15] H. Schuitemaker,et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans , 2021, Nature.
[16] Karen L. Price,et al. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. , 2021, JAMA.
[17] A. Copas,et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study , 2021, The Lancet Infectious Diseases.
[18] P. Dormitzer,et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans , 2021, Nature.
[19] M. Hassany,et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. , 2021, JAMA.
[20] E. Callaway. Mix-and-match COVID vaccines trigger potent immune response , 2021, Nature.
[21] P. Khavari,et al. SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity , 2021, The Lancet Infectious Diseases.
[22] G. Ciliberto,et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution , 2021, Journal of Hematology & Oncology.
[23] K. Watsky,et al. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series. , 2021, JAMA dermatology.
[24] D. Moodley,et al. Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant , 2021, The New England journal of medicine.
[25] L. Abu-Raddad,et al. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.
[26] M. Maus,et al. SARS -CoV-2 T-cell immunity to variants of concern following vaccination , 2021, bioRxiv.
[27] David A. Drew,et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study , 2021, The Lancet Infectious Diseases.
[28] H. Fennema,et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.
[29] M. Kaiser,et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma , 2021, The Lancet Haematology.
[30] D. Ho,et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization , 2021, Cell Host & Microbe.
[31] M. Dimopoulos,et al. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose , 2021, Blood.
[32] J. Bussel,et al. SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia , 2021, The New England journal of medicine.
[33] D. Goldblatt,et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination , 2021, The New England journal of medicine.
[34] Andreas Greinacher,et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination , 2021, The New England journal of medicine.
[35] A. Kenig,et al. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products , 2021, Clinical Immunology.
[36] J. Mascola,et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 , 2021, The New England journal of medicine.
[37] anonymous. An EUA for bamlanivimab and etesevimab for COVID-19. , 2021, The Medical letter on drugs and therapeutics.
[38] A. Hurt,et al. Neutralizing Antibody Therapeutics for COVID-19 , 2021, Viruses.
[39] J. Wrammert,et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant , 2021, Cell Host & Microbe.
[40] S. Madhi,et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant , 2021, The New England Journal of Medicine.
[41] N. G. Davies,et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, Nature.
[42] William T. Harvey,et al. Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.
[43] V. Simon,et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine , 2021, The New England journal of medicine.
[44] M. Landray,et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.
[45] P. Dormitzer,et al. Neutralizing Activity of BNT162b2-Elicited Serum , 2021, The New England journal of medicine.
[46] V. Gushchin,et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia , 2021, The Lancet.
[47] Elisabeth Mahase. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant , 2021, BMJ.
[48] J. Gunst,et al. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses , 2021, EBioMedicine.
[49] F. Polack,et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma therapy , 2021, The New England Journal of Medicine.
[50] Paige G. Wickner,et al. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach , 2020, The Journal of Allergy and Clinical Immunology: In Practice.
[51] E. Phillips,et al. Maintaining Safety with SARS-CoV-2 Vaccines , 2020, The New England journal of medicine.
[52] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[53] John D. Davis,et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 , 2020, The New England journal of medicine.
[54] A. Iafrate,et al. COVID-19-neutralizing antibodies predict disease severity and survival , 2020, Cell.
[55] Ping Li,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020 .
[56] Nguyen H. Tran,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.
[57] J. Mascola,et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination , 2020, The New England journal of medicine.
[58] H. Einsele,et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set , 2020, Blood.
[59] W. Wood,et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients , 2020, Blood.
[60] A. Iafrate,et al. COVID-19 neutralizing antibodies predict disease severity and survival , 2020, medRxiv.
[61] H. Larson,et al. Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study , 2020, The Lancet.
[62] G. Morgan,et al. COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers , 2020, Blood cancer discovery.
[63] Nguyen H. Tran,et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.
[64] S. Jagannath,et al. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward , 2020, Journal of Hematology & Oncology.
[65] J. San-Miguel,et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality , 2020, Blood Cancer Journal.
[66] M. Koopmans,et al. Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients , 2020, Haematologica.
[67] M. Jenner,et al. Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy , 2020, British journal of haematology.
[68] R. Baric,et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.
[69] C. Weyand,et al. Influence of immune aging on vaccine responses , 2020, Journal of Allergy and Clinical Immunology.
[70] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[71] G. Gahrton,et al. Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma , 2019, PloS one.
[72] T. Bamdad,et al. Lenalidomide acts as an adjuvant for HCV DNA vaccine , 2017, International immunopharmacology.
[73] R. Greil,et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site , 2016, Journal of Hematology & Oncology.
[74] D. Jayne,et al. SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .
[75] N. Nassif,et al. Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade , 2016, Leukemia.
[76] U. Mellqvist,et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients , 2015, Haematologica.
[77] U. Mellqvist,et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study , 2012, Haematologica.
[78] C. Huff,et al. Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses , 2012, Clinical Cancer Research.
[79] C. Wennerås,et al. Comparative Study of Immune Status to Infectious Agents in Elderly Patients with Multiple Myeloma, Waldenstrom's Macroglobulinemia, and Monoclonal Gammopathy of Undetermined Significance , 2011, Clinical and Vaccine Immunology.
[80] Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings , 2020 .
[81] K. McCullough,et al. Self-Replicating RNA Vaccine Delivery to Dendritic Cells. , 2017, Methods in molecular biology.